Overview

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Onassis Cardiac Surgery Centre

Treatments:

Iloprost